Meeting
2019 ASCO Annual Meeting
The tumor microenvironment in EGFR-driven loco-regional lung adenocarcinoma can predict higher risk of recurrence.
Authors
Maya Khalil
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Maya Khalil , Ahmed Elkhanany , Yuanquan Yang , Sean Glenn , Antonios Papanicolau-Sengos , Carl Morrison , Grace K. Dy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8521)
DOI
10.1200/JCO.2019.37.15_suppl.8521
Abstract #
8521
Poster Bd #
277
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Furmonertinib as adjuvant therapy in postoperative EGFR-mutated stage IA2-IIIA non-small cell lung cancer (NSCLC) with high-risk pathological factors.
First Author: Ziheng Wu
Poster
2018 ASCO Annual Meeting
Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC).
First Author: Lee Chun Park
Poster
2021 ASCO Annual Meeting
Immune contexture in high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 randomized trial.
First Author: Sandro Pasquali
Poster
2018 ASCO Annual Meeting
EGFR reporting in stage IV adenocarcinoma of the lung: Demographic predictors of EGFR testing and survival.
First Author: Shagufta Shaheen